In recent years, a meta-analysis of phase III clinical trials evaluating novel combination therapy regimens for unresectable HCC has demonstrated that dual immunotherapy combining anti-PD-1/PD-L1 and anti-CTLA-4 inhibitors exhibits promising antitumor activity [75]. This evidence concerns the gene CD274 and hepatocellular carcinoma.